The National Eye Institute (NEI) seeks research co-development partners and/or licensees for single-cell RNA sequencing (scRNA-seq) analysis software that leverages existing large language models (LLM) to simplify and enhance data analysis by providing intelligent recommendations and interpretations.
The National Eye Institute (NEI) seeks research co-development partners and/or licensees for a thermosensitive, pro-angiogenic material designed for 3D bioprinting.
The groundbreaking technology of high-frequency cell mechanics assessment represents a paradigm shift in the field of cell analysis. This innovation enables rapid and non-invasive evaluation of cell health and viability, eliminating the need for cell labeling or modification. By measuring cell viscoelastic properties at high frequencies, it offers real-time insights into the mechanical characteristics of individual cells and entire populations.
The technology at hand involves a rabbit polyclonal antibody specifically designed for the human Sun1 inner nuclear envelope protein, even though it is directed against the mouse Sun1 inner nuclear membrane protein. Sun1 is known to be an inner nuclear envelope protein, and defects in such proteins can lead to debilitating conditions like Emery-Dreifuss muscular dystrophy and Hutchinson Gilford Progeria Syndrome. Importantly, the antibody serves as a valuable tool for diagnostic and analytical studies concerning cells afflicted with nuclear envelope defects.
The technology involves the development of novel PCSK9 immunogens that are specifically designed to eliminate sequence overlap with human proteins, thereby reducing potential self-reactivity and immunogenicity issues. By selectively grafting epitope residues from non-human PCSK9 or structurally similar sequences onto the epitope-scaffold, these immunogens can induce an immune response against the PCSK9 enzyme without triggering a significant reaction against the body’s own proteins.
We are seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this technology.
This technology includes a vaccine for lowering plasma triglycerides by inducing the formation of autoantibodies against either ANGPTL3 or ANGPTL4, which are inhibitors of Lipoprotein Lipase. This was done by conjugating synthetic peptides based on ANGPTL3 or ANGPTL4 to virus- like particles (VLPS). Injection of the vaccine in animal models was shown to induce the autoantibody against the target and to lower plasma triglycerides.